Manufacturer of Controlled Substances; Notice of Application, 36577-36578 [2011-15481]

Download as PDF 36577 Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(d)–(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. ¨ The Sud-Chemie respondents may present to the presiding ALJ the matter raised in their June 6, 2011 confidential letter to the Commission. proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either emailed to pubcommentees.enrd@usdoj.gov or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to United States v. Swift Beef Company, Civil Action No. 8:11– cv–216 (D. Neb.), DJ Reference No. 90– 5–1–1–09466. During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site: https://www.usdoj. gov/enrd/Consent_Decrees.html. A copy of the proposed consent decree may be obtained by mailing a request to the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611. When requesting a copy by mail, please enclose a check payable to the U.S. Treasury in the amount of $12.00 (25 cents per page reproduction cost). A copy may also be obtained by faxing or e-mailing a request to Tonia Fleetwood, tonia.fleetwood@usdoj.gov, fax number (202) 514–0097, phone confirmation number (202) 514–1547, and sending a check to the Consent Decree Library at the stated address. By order of the Commission. Issued: June 16, 2011. James R. Holbein, Secretary to the Commission. Robert E. Maher, Jr., Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2011–15534 Filed 6–21–11; 8:45 am] [FR Doc. 2011–15465 Filed 6–21–11; 8:45 am] BILLING CODE 7020–02–P BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE mstockstill on DSK4VPTVN1PROD with NOTICES Notice of Lodging of Consent Decree Pursuant to the Clean Water Act Notice is hereby given that on June 16, a proposed Consent Decree in United States and the State of Nebraska v. Swift Beef Company, Civil Action No. 8:11–cv–216 was lodged with the United States Court for the District of Nebraska. In this action, Plaintiffs the United States and State of Nebraska sought the penalties and injunctive relief for violations of the Clean Water Act (‘‘CWA’’) by Swift Beef Company (‘‘Swift’’) at a beef processing plant it owns and operates in Grand Island, Nebraska. Pursuant to the proposed Consent Decree, Defendants will pay to the United States and the State of Nebraska $1,300,000 in civil penalties and undertake injunctive measures designed to prevent future violations. For 30 days after the date of this publication, the Department of Justice will receive comments relating to the VerDate Mar<15>2010 16:40 Jun 21, 2011 Jkt 223001 Drug Enforcement Administration for distribution and sale to its customers. Regarding (9640) the company plans to manufacture another controlled substance for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 22, 2011. Dated: June 14, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–15478 Filed 6–21–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 4, 2011, Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805–9372, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 11, 2011, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Gamma Hydroxybutyric Acid (2010). Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Tapentadol (9780) ........................ I II II II II The company plans to manufacture the listed controlled substances in bulk PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Drug Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Methadone (9250) ........................ Methadone Intermediate (9254) ... Schedule II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, E:\FR\FM\22JNN1.SGM 22JNN1 36578 Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices Springfield, Virginia 22152; and must be filed no later than August 22, 2011. Dated: June 13, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–15481 Filed 6–21–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated March 9, 2011, and published in the Federal Register on March 17, 2011, 76 FR 14689, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: mstockstill on DSK4VPTVN1PROD with NOTICES Drug Schedule Tetrahydrocannabinols (7370) ..... Codeine-N-oxide (9053) ............... Dihydromorphine (9145) ............... Difenoxin (9168) ........................... Morphine-N-oxide (9307) ............. Normorphine (9313) ..................... Norlevorphanol (9634) .................. Amphetamine (1100) .................... Methamphetamine (1105) ............ Drug Schedule. Methylphenidate (1724) ................ Nabilone (7379) ............................ Codeine (9050) ............................. Diprenorphine (9058) ................... Etorphine HCL (9059) .................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Metopon (9260) ............................ Dextropropoxyphene, bulk (9273) Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ VerDate Mar<15>2010 16:40 Jun 21, 2011 I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II Jkt 223001 The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Mallinckrodt, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Mallinckrodt, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: June 14, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–15482 Filed 6–21–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employee Benefits Security Administration 156th Meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans; Notice of Meeting Pursuant to the authority contained in Section 512 of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, the 156th open meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans; (also known as the ERISA Advisory Council) will be held on July 19–21, 2011. The three-day meeting will take place in C–5515 Room 1–A, U.S. Department of Labor, 200 Constitution Avenue, NW., Washington, DC 20210. The purpose of the open meeting is for Advisory Council members to hear testimony from invited witnesses and to receive an update from the Employee Benefits Security Administration (EBSA). The meeting will run from 9 a.m. to approximately 5 p.m. on July 19 and from 8:30 a.m. to approximately 5 p.m. on July 20 and 21, with a one hour break for lunch each day. The EBSA update is scheduled for the afternoon of July 20, subject to change. PO 00000 Frm 00067 Fmt 4703 Sfmt 9990 The Advisory Council will study the following issues: (1) Hedge Funds and Private Equity Investments, (2) Privacy and Security Issues Affecting Employee Benefit Plans (other than health care plans), and (3) Current Challenges and Best Practices for ERISA Compliance for 403(b) Plan Sponsors. The schedule for testimony and discussion of these issues generally will be one issue per day in the order noted above. Descriptions of these topics are available on the Advisory Council page of the EBSA Web site, at https://www.dol.gov/ebsa/ aboutebsa/erisa_advisory_council.html. Organizations or members of the public wishing to submit a written statement may do so by submitting 30 copies on or before July 12, 2011 to Larry Good, Executive Secretary, ERISA Advisory Council, U.S. Department of Labor, Suite N–5623, 200 Constitution Avenue, NW., Washington, DC 20210. Statements also may be submitted as e-mail attachments in text or pdf format transmitted to good.larry@dol.gov. It is requested that statements not be included in the body of the e-mail. Statements deemed relevant by the Advisory Council and received on or before July 12, 2011 will be included in the record of the meeting and available in the EBSA Public Disclosure room, along with witness statements. Do not include any personally identifiable information (such as name, address, or other contact information) or confidential business information that you do not want publicly disclosed. Written statements submitted by invited witnesses also will be posted, without change, on the Advisory Council page of the EBSA Web site—https:// www.dol.gov/ebsa/. Statements posted on the Internet can be retrieved by most Internet search engines. Individuals or representatives of organizations wishing to address the Advisory Council should forward their requests to the Executive Secretary or telephone (202) 693–8668. Oral presentations will be limited to ten minutes, time permitting, but an extended statement may be submitted for the record. Individuals with disabilities who need special accommodations should contact the Executive Secretary by July 12 at the address indicated. Signed at Washington, DC, this 17th day of June 2011. Michael L. Davis, Deputy Assistant Secretary, Employee Benefits Security Administration. [FR Doc. 2011–15587 Filed 6–21–11; 8:45 am] BILLING CODE 4510–29–P E:\FR\FM\22JNN1.SGM 22JNN1

Agencies

[Federal Register Volume 76, Number 120 (Wednesday, June 22, 2011)]
[Notices]
[Pages 36577-36578]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-15481]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 4, 2011, Boehringer 
Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 
23805-9372, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers for formulation into finished 
pharmaceuticals.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive,

[[Page 36578]]

Springfield, Virginia 22152; and must be filed no later than August 22, 
2011.

    Dated: June 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-15481 Filed 6-21-11; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.